Temozolomide
NDC Package 70301-2011-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Temozolomide is a medication used to treat certain types of brain cancer. Marketed by Opko Pharmaceuticals, Llc, this product is identified by NDC 70301-2011 and is authorized under FDA application ANDA203898.

Identification & Billing

NDC Package Code
70301-2011-1
Package Description
5 PACKET in 1 CARTON / 1 CAPSULE in 1 PACKET
Product Code
70301-2011
11-Digit Billing Format
70301201101

Clinical Specifications

Proprietary Name
Temozolomide
Dosage Form
-
Usage Information
This medication is used to treat certain types of brain cancer. Temozolomide belongs to a class of drugs known as alkylating agents. It works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Opko Pharmaceuticals, Llc
FDA Application #
ANDA203898
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-15-2026
End Marketing Date
06-15-2026
Listing Expiration
06-15-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70301-2011-1 identifies a specific commercial package of 5 packet in 1 carton / 1 capsule in 1 packet of Temozolomide, labeled by Opko Pharmaceuticals, Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Opko Pharmaceuticals, Llc on June 15, 2026. The current certification is valid through June 15, 2026.

What are the primary indications for this medication?

This medication is used to treat certain types of brain cancer. Temozolomide belongs to a class of drugs known as alkylating agents. It works by slowing or stopping the growth of cancer cells.

How is this Opko Pharmaceuticals, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70301201101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70301-2011-1
11-Digit CMS (5-4-2)
70301-2011-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.